Heidi M. Davis
Executive Vice President, Business Development & Co-founder
Heidi has nearly 25 years of clinical research experience in developing strategic business development relationships. Heidi began her career in research at a leading psychiatric research clinic in southern California. As the site manager, she oversaw the daily operations for 4 outpatient clinics and an inpatient CRU.
For the past 11 years, Heidi has managed early and late stage business development activities for site networks. She has been instrumental in identifying new therapeutic targets and working with clinical operations to implement new capabilities across multiple sites.
Additionally, Heidi was responsible for coordinating 2 Scientific Advisory Board meetings for sponsors developing drugs in Schizophrenia and Alzheimer’s. Heidi is based in southern California.
Jason M. HovLand, M.S.
Executive Vice President, Business Development & Co-founder
Jason has more than 10 years of industry experience and holds a Master’s degree in Pharmacology & Toxicology. While attending graduate school, he worked in the Department of Pharmacy at the New York-Presbyterian-Cornell Campus.
Jason served as a director of business development for a large site network, where he was responsible for establishing and managing key sponsor/CRO relationships, including facilitating protocol reviews.
Leveraging his background in pharmacy, Jason has worked with sites to incorporate complex compounding logistics in the execution of sponsor protocols. In late 2019, Jason assumed the role of interim head of business development, managing a five-member team and all business development activities. Jason is based in New York City.
Jerry Cruz
Executive Vice President, Business Operations & co-founder
Jerry has more than 30 years of industry experience, at CROs, Core Labs, and Investigational Sites, working in clinical operations, MIS, strategic alliances and business development.
As a business manager, Jerry was responsible for reporting company performance to executive management and sales support to multiple business development teams. Jerry graduated from Georgetown University with a BA in Economics. He is highly experienced in managing large, disparate business information. Jerry is based in Pennsylvania.
Rick Mofsen, D.O.
Medical Advisor
Dr. Rick Mofsen has decades of experience in multi-level management of clinical trials with a particular focus on the promotion and standardization of ethical, accurate, and scrupulous practices across clinical research sites. To this end, Dr. Mofsen brings a career of expertise in the practical implementation of psychometric instruments, centralized protocol development, and trial design. Dr. Mofsen also has the privilege to serve as a current member of the ethics committee for the Schizophrenia International Research Society.
Dr. Mofsen's research interests include leveraging advances in biotechnology, data science, genetics and neuroimaging to improve the precision and accuracy of clinical trial endpoints. He is an especially firm believer in cross-collaboration and open-sourced data practices, which he hopes will facilitate the development of instruments better equipped to assess the safety and efficacy of CNS interventions prior to institutional or corporate over-investment.
Mason Freeman, M.D.
Medical Advisor
Dr. Mason Freeman graduated from Harvard College and received his MD at the University of California, San Francisco. He served as an intern, resident, endocrinology fellow, and Chief Resident in Medicine in the Department of Medicine at Massachusetts General Hospital. He trained as a postdoctoral research fellow in the Biology Department of the Massachusetts Institute of Technology, where he played a central role in cloning the first macrophage scavenger receptor to be molecularly identified.
He became Chief of the Lipid Metabolism Unit at Mass General in 1992 and continues to direct that unit as well as the Translational Medicine programs of both the Mass General Center for Computational and Integrative Biology (CCIB) and the Division of Clinical Research.
From 2005-2007, while on a leave of absence from Harvard, he served as a head of the Novartis Translational Medicine program for Cardiovascular & Metabolic Diseases, as well as the company’s Global Head of Biomarker Development. Dr. Freeman has served as a consultant to multiple life science startup companies either independently or through his role as a venture partner at 5AM Ventures, an early-stage life science venture firm.
At 5AM, he has contributed to the creation of over 30 companies, serving on the boards of Crinetics and Envoy Therapeutics, a neuroscience company acquired by Takeda in 2012.
Dr. Freeman also played a key medical advisor role at Relypsa, which developed the first chronic oral therapy for hyperkalemia approved by the FDA in over 50 years.
He is a Professor of Medicine at Harvard Medical School and editor of the Adult Primary Care lipid section of UpToDate, one of the world’s most widely read and cited on-line medical textbooks.